• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Quality by design engineered, enhanced anticancer activity of temozolomide and resveratrol coloaded NLC and brain targeting via lactoferrin conjugation in treatment of glioblastoma
The objective of the work was to engineer lactoferrin conjugated temozolomide and resveratrol co-loaded NLC for the treatment of glioblastoma using intranasal delivery for brain targeting. Synergistic activity of temozolomide and resveratrol was determined using combination index method and 1:1 ratio was selected. QbD approach was used to formulate and optimize NLC, with minimum particle size, maximum transmittance and entrapment efficiency using Central Composite Rotable Design (CCRD) method. The optimized LTR-NLC had desired average particle size (209.3 nm), narrow PDI along, high percentage transmittance (>95%) and b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - August 30, 2023 Category: Drugs & Pharmacology Authors: Saurabh Mittal Sadia Shah Harlokesh Narayan Yadav Javed Ali Madan Mohan Gupta Sanjula Baboota Source Type: research

Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
CONCLUSIONS: Combination of PAC-1 and TMZ was well tolerated up to 625 mg orally daily and TMZ orally 150 mg/m2/5 days per 28-day cycle. The maximum tolerated dose was not reached. Further dose escalation of PAC-1 in combination with TMZ is advised before conducting a formal prospective efficacy study in this patient population.PMID:37554223 | PMC:PMC10406430 | DOI:10.1093/noajnl/vdad087
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Matthias Holdhoff M Kelly Nicholas Richard A Peterson Stefania Maraka Li C Liu James H Fischer Jeffrey S Wefel Timothy M Fan Tracy Vannorsdall Meredith Russell Michaella Iacoboni Theodore M Tarasow Paul J Hergenrother Arkadiusz Z Dudek Oana C Danciu Source Type: research

Quantitative profiling of genes associated with cancer pathways in brain tumors
CONCLUSION: Based on the obtained data, we can conclude that individual diagnoses differ in transcriptomic profile. An individual molecular approach is therefore necessary in order to provide comprehensive and targeted therapy on multiple metabolic pathways in the diagnosis of brain tumors.PMID:37353350 | DOI:10.48095/ccko2023224
Source: Cancer Control - June 23, 2023 Category: Cancer & Oncology Authors: Z Majer číková K Dibdiakov á M Galanda T Galanda R Richterov á B Kolarovszki P Ra čay J Hatok Source Type: research

MicroRNA-640 Inhibition Enhances the Chemosensitivity of Human Glioblastoma Cells to Temozolomide by Targeting Bcl2 Modifying Factor
Biochem Genet. 2022 Aug 19. doi: 10.1007/s10528-022-10264-x. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most malignant and challenging type of astrocytoma and also notoriously acknowledged as the most common primary brain tumor globally. Currently, chemotherapy is the most master therapy for tumor and is essential in clinical treatment for GBM. Nevertheless, the characterization of chemotherapy resistance seriously hinders clinical chemotherapy treatment. Accordingly, there are imperious demands for the exploitation of novel chemosensitizer to promote the efficacy of chemotherapy. Our current study was conduct...
Source: Biochemical Genetics - August 19, 2022 Category: Genetics & Stem Cells Authors: Shu Jiang Chao Luo Yongli Chen Jing Chen Shuang Tao Quan Zou Chunzhi He Shanwu Dong Source Type: research

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3 β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
CONCLUSION: 9-ING-41 plus/minus lomustine is safe and warrants further study in glioma patients.PMID:35402914 | PMC:PMC8989389 | DOI:10.1093/noajnl/vdac012
Source: Adv Data - April 11, 2022 Category: Epidemiology Authors: Yazmin Odia Ludimila Cavalcante Howard Safran Steven Francis Powell Pamela N Munster Wen Wee Ma Benedito A Carneiro Bruno R Bastos Stacy Mikrut William Mikrut Francis J Giles Solmaz Sahebjam Source Type: research

Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma
CONCLUSIONS: LMF in combination with temozolomide and bevacizumab was well tolerated in patients with recurrent IDH wild-type high-grade glioma. This small study did not establish a superior efficacy with addition of LMF compared to standard bevacizumab therapy, however, this study did show methylome reprogramming in high-grade glioma.PMID:35392283 | PMC:PMC8983000 | DOI:10.1158/2767-9764.CRC-21-0088
Source: Cancer Control - April 8, 2022 Category: Cancer & Oncology Authors: Lucas A Salas Thomas G Stewart Bret C Mobley Chengwei Peng Jing Liu Sudan N Loganathan Jialiang Wang Yanjun Ma Mitchell S Berger Devin Absher Yang Hu Paul L Moots Brock C Christensen Stephen W Clark Source Type: research

Executive summary of american radium society's appropriate use criteria for the postoperative management of lower grade gliomas
Radiother Oncol. 2022 Mar 31:S0167-8140(22)00156-6. doi: 10.1016/j.radonc.2022.03.018. Online ahead of print.ABSTRACTPostoperative management of lower grade gliomas (grade 2 and 3) is heterogeneous. The American Radium Society's brain malignancies panel systematically reviewed and evaluated the literature to develop consensus guidelines addressing timing of postoperative therapy, monotherapy versus combined modality therapy, type of chemotherapy used with radiotherapy, and radiotherapy dose. Thirty-six studies were included. Using consensus methodology (modified Delphi), the panel voted upon representative case variants us...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 3, 2022 Category: Radiology Authors: Martin C Tom Michael T Milano Samuel T Chao Scott G Soltys Jonathan P S Knisely Arjun Sahgal Seema Nagpal Simon S Lo Siavash Jabbari Tony J C Wang Manmeet S Ahluwalia Marian Simonson Joshua D Palmer Melanie Hayden Gephart Lia M Halasz Amit K Garg Veronica Source Type: research

Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics
CONCLUSION: Our integrated analysis allows to evaluate and redefine co-methylation domains within the MGMT promoter and to rationalize the practical impact on assays used in daily routine diagnostics.PMID:35180887 | DOI:10.1186/s13148-022-01244-4
Source: Clin Med Res - February 19, 2022 Category: Research Authors: Sascha Tierling Wiebke M J ürgens-Wemheuer Alea Leismann Julia Becker-Kettern Michael Scherer Arne Wrede David Breuskin Steffi Urbschat Christoph Sippl Joachim Oertel Walter J Schulz-Schaeffer J örn Walter Source Type: research

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma
Transl Oncol. 2022 Feb 16;18:101368. doi: 10.1016/j.tranon.2022.101368. Online ahead of print.ABSTRACTClinical outcomes in patients with WHO grade II/III astrocytoma, oligodendroglioma or secondary glioblastoma remain poor. Isocitrate dehydrogenase 1 (IDH1) is mutated in > 70% of these tumors, making it an attractive therapeutic target. To determine the efficacy of our newly developed mutant IDH1 inhibitor, SYC-435 (1-hydroxypyridin-2-one), we treated orthotopic glioma xenograft model (IC-BT142AOA) carrying R132H mutation and our newly established orthotopic patient-derived xenograft (PDX) model of recurrent anaplastic ...
Source: Ann Oncol - February 19, 2022 Category: Cancer & Oncology Authors: Mari Kogiso Lin Qi Yuchen Du Frank K Braun Huiyuan Zhang L Frank Huang Lei Guo Yulun Huang Wan-Yee Teo Holly Lindsay Sibo Zhao Sarah G Injac Zhen Liu Vidya Mehta Diep Tran Feng Li Patricia A Baxter Jack M Su Laszlo Perlaky D Williams Parsons Murali Chinta Source Type: research

Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics
CONCLUSION: Our integrated analysis allows to evaluate and redefine co-methylation domains within the MGMT promoter and to rationalize the practical impact on assays used in daily routine diagnostics.PMID:35180887 | DOI:10.1186/s13148-022-01244-4
Source: Clin Med Res - February 19, 2022 Category: Research Authors: Sascha Tierling Wiebke M J ürgens-Wemheuer Alea Leismann Julia Becker-Kettern Michael Scherer Arne Wrede David Breuskin Steffi Urbschat Christoph Sippl Joachim Oertel Walter J Schulz-Schaeffer J örn Walter Source Type: research

Pages: 1  2  3